NCT01525368

Brief Summary

Cognitive training has been shown to be successful in patients with amnestic mild cognitive impairment (aMCI), a group at high-risk for Alzheimer's disease (AD). Moreover, in a randomized controlled trial, the investigators recently found that aMCI patients receiving a cognitive intervention showed stable hypometabolism in FDG-PET, whereas patients in an active control group showed pronounced hypometabolism on follow-up scans in regions typically affected in AD. Previous studies indicate that not all patients respond equally well to a cognitive intervention. Identifying factors that predict response to treatment could help selecting patients for a targeted intervention. A potentially important predictor is cognitive reserve defined as premorbid cognitive performance. The hypothesis is that different levels of cognitive reserve (high cognitive reserve vs. low cognitive reserve) have different neurostructural and neurofunctional correlates and influence treatment response in a different way. Moreover, the impact of white matter lesions on treatment effects will be investigated. The investigator will perform a complex cognitive training program. Forty patients with aMCI (20 with high cognitive reserve, 20 with low cognitive reserve) will be recruited in this study. Since the patients are recruited consecutively, an estimated overall number of 80 will be included and receive the training of whom about 40 will meet the inclusion criteria for our cognitive-reserve-study (high or low cognitive reserve). Data of the whole group will be used to analyze the potential impact of white matter lesions on response to the intervention. Cognitive effects of the intervention will be evaluated by neuropsychological testing. Neurofunctional and neurostructural changes depending on cognitive reserve will be measured using resting state fMRI and diffusion tensor imaging (DTI). For comparison, a group of 30 aMCI patients will be recruited as an active control group receiving study investigations (neuropsychological testing as well as MRIs), and exercises for self-study at home, not the complex cognitive intervention.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2010

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2010

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

January 24, 2012

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 2, 2012

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2014

Completed
Last Updated

November 13, 2014

Status Verified

November 1, 2014

Enrollment Period

3.8 years

First QC Date

January 24, 2012

Last Update Submit

November 11, 2014

Conditions

Keywords

mild cognitive impairmentAlzheimer's diseasecognitive interventioncognitive reserve

Outcome Measures

Primary Outcomes (3)

  • Change in California Verbal Learning Test

    month 0 and month 6

  • Change in overall cognition (ADAScog)

    month 0 and month 6

  • Change in Face-Name Learning Test

    month 0 and month 6

Secondary Outcomes (7)

  • Change in appraisal of quality of life (SF-36)

    month 0 and 6

  • Change in neurofunctional MRT (resting state fMRI)

    month 0 and 6

  • Change in depression scores (Beck Depression Inventory)

    month 0 and month 6

  • Change in working memory (Digit Span)

    month 0 and month 6

  • Change in attention (Trail Making Test)

    month 0 and month 6

  • +2 more secondary outcomes

Study Arms (2)

cognitive intervention group

Behavioral: cognitive intervention

active control group

Interventions

Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.

cognitive intervention group

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Consecutive aMCI patients of an University-based memory clinic

You may qualify if:

  • male or female patients, fulfilling Petersen´s criteria of amnestic mild cognitive impairment (aMCI)
  • No evidence for other psychiatric axis I disorders according to DSM-IV criteria.
  • No evidence for neurological disorders (e.g. stroke)
  • No uncontrolled arterial hypertension or diabetes mellitus
  • No history of drug / alcohol abuse
  • The patient is able to provide written informed consent to participate in the study.
  • for the cognitive-reserve-study patients, a high (low) cognitive reserve is defined as a verbal IQ score of \>/= 120 (\</= 110) as assessed by the MWT-B, a German multiple vocabulary test

You may not qualify if:

  • Evidence for acute psychiatric or neurological disorders
  • Uncontrolled arterial hypertension or diabetes mellitus
  • History of drug / alcohol abuse
  • No ability to participate and no willing to give informed consent and comply with the study restrictions.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute for Stroke and Dementia Research, Campus Grosshadern, Ludwig-Maximilian University

Munich, 81377, Germany

Location

MeSH Terms

Conditions

Cognitive DysfunctionAlzheimer Disease

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Katharina Buerger, MD, Institute for Stroke and Dementia Research

Study Record Dates

First Submitted

January 24, 2012

First Posted

February 2, 2012

Study Start

September 1, 2010

Primary Completion

July 1, 2014

Study Completion

July 1, 2014

Last Updated

November 13, 2014

Record last verified: 2014-11

Locations